Ann: Quarterly Cashflow Report, page-4

Taken from the Quarterly report.
The last 3 points particularly interesting.
Appears that new DEP candidates selected for development both internally & externally.
Looking good. The next 6months should be very interesting indeed.

"Starpharma’s cash balance as at 30 June 2018 was $51.3 million. The net cash-burn for the
financial year was $9.9 million which is just over half of last year’s net cash-burn (excluding
net proceeds from the agribusiness sale) of $18.1 million."​

"Outlook
 VivaGel® BV US licence
 VivaGel® BV launch in Australia, Europe & other Mundipharma regions
 VivaGel® BV US regulatory approval & approval in Mundipharma regions
 Revenue from VivaGel® BV milestones, supply & sales
 Further VivaGel® condom regulatory approvals and product launches in multiple regions
(e.g. Japan, China, EU)
 Progress with DEP® docetaxel & DEP® cabazitaxel clinical trials
 DEP® irinotecan to advance to the clinic
 New DEP® candidates selected for further development
 AstraZeneca program developments, e.g. AZD0466 advanced to the clinic & revenue from
milestones; further compounds advanced​

 Other partnered DEP® deals and program developments, including for Targeted DEP®"